Ahmad Mattour, MD
Hematology · Detroit, MINPI 1497980635
Payments from drug & device makers
Across 195 payments — averaging $4276.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$423K
- Novartis$104K
- Takeda Pharmaceuticals U.S.A., Inc.$91K
- Otsuka Pharmaceutical Co., Ltd.$58K
- Bristol Myers Squibb$38K
- E.r. Squibb & Sons, L.L.C.$34K
- plus $86K from 22 others
Across 8 payments — averaging $148.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmacyclics LLC, An Abbvie Company$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $423,203 |
| Novartis | 4 | $104,046 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $90,810 |
| Otsuka Pharmaceutical Co., Ltd. | 4 | $57,951 |
| Bristol Myers Squibb | 10 | $37,675 |
| E.r. Squibb & Sons, L.L.C. | 9 | $34,214 |
| Astellas Pharma Global Development | 12 | $19,918 |
| AstraZeneca | 20 | $11,742 |
| ADC Therapeutics America, Inc. | 6 | $9,714 |
| Amgen | 1 | $8,000 |
| Incyte Corporation | 10 | $7,556 |
| PTC Therapeutics, Inc. | 2 | $6,987 |
| Karyopharm Therapeutics Inc. | 12 | $6,498 |
| Pharmacosmos Therapeutics Inc. | 10 | $3,953 |
| CTI Biopharma Corp. | 2 | $3,282 |
| GSK | 1 | $3,250 |
| Janssen Scientific Affairs, LLC | 1 | $1,635 |
| Beigene USA, Inc. | 4 | $940 |
| Daiichi Sankyo Inc. | 2 | $850 |
| Ares Trading SA | 2 | $630 |
| Beigene, Ltd. | 1 | $525 |
| Sobi, Inc | 1 | $200 |
| Beone Medicines USA, Inc. | 1 | $123 |
| Seagen Inc. | 1 | $106 |
| Exelixis Inc. | 1 | $66 |
| Gilead | 1 | $35 |
| Bayer | 1 | $23 |
| Lilly USA, LLC | 1 | $15 |
How this compares
$833,946 in reported general payments places this provider in the 85th percentile of 50 hematology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Detroit
- Maria DiabDetroit$831K
- Asif AlaviDetroit$828K
- Andrew KinDetroit$461K
- Hiba Jabbour-AidaDetroit$38K
- Paul SwerdlowDetroit$14K
- Matthew PiankoAnn Arbor$5.7M
- Yasmin KarimiAnn Arbor$3M
- Dahlia SanoAnn Arbor$3M
- Sarah AnandAnn Arbor$2.5M
- Erica CampagnaroAnn Arbor$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.